---
ticker: "CLS"
company: "Celestica Inc."
date: "2026-10-26"
view: "Buy"
fair_value: 281.2
price: 246.65
price_source: "market data historical-price-eod close, 2026-10-26 (alpha market-data fetch); market data quote 246.40 at 20:00 UTC"
price_time: "2026-10-26T20:00:00Z"
price_vs_fair_value: "-12.3%"
bear: 111.16
bull: 620.19
exit_price: 467.42
p_price_justified: "over 50%"
restated: "2026-10-26"
method: "case-spread-2026-10-24"
original_fair_value: 281
original_view: "Buy"
page: "https://alpha.dming.si/research/2026-10-26-cls-2"
---

# CLS · Celestica Inc. · Buy

Research report as of 2026-10-26, unblinded. Page: https://alpha.dming.si/research/2026-10-26-cls-2

We value CLS at $281 a share. The report's $246.65 price (Oct 26, 2026) was 12% below fair value: Buy.

_Restated Oct 26, 2026 (method case-spread-2026-10-24); the report's original value was $281, Buy._

| Lens | Range | Marks |
| --- | --- | --- |
| Our report | $111 to $620 | fair $281; original $281 |
| Our simulation | $122 to $645 | median $281 |
| Street targets (11) | $375 to $520 | average $456, median $460 |
| Price | | $246.65 |

Bands run from our bear to bull (the hollow mark is the original $281), our simulation's 10th to 90th percentile and the Street's low to high. Street targets forecast future prices, not value today. Market data, captured Oct 26, 2026.

| Figure | Value |
| --- | --- |
| Fair value | $281 |
| Price | $246.65 (market data, Oct 26, 1:00 PM PT) |
| Five-year return | 13.1% (a year, at the report's price) |
| Bear / bull | $111 / $620 |
| Exit price | $467 (on Dec 31, 2031) |
| Confidence | 30% |
| Price against our scenarios | The price is justified in over 50% of our scenarios (4,000 simulated outcomes, each drawing the uncertain drivers from ranges we chose: our judgement, not a measured chance) |

**What the price needs.** Any one of these, on its own, would justify the price:

- 2027 revenue vs our path ($M): needs -5,241, we have 0
- CCS growth 2028-31 vs our path: needs -5.1%, we have 0.0%
- CCS margin vs our path: needs -0.9%, we have 0.0%

_This text argues the original call. The current figures are at the top._

**Original call, Oct 26, 2026 (before the Oct 26, 2026 restatement)**

```
CLS — Celestica Inc. (NYSE, TSX) — research view (market: Buy)
As of 2026-10-26 · unblinded: this revises the 2026-10-15 report, whose market
pass recorded the price ($315.27 at the 2026-10-15 close), the Street's
targets and its revenue estimates; the analyst read that report before
building this model. The Q3 2026 10-Q also prints the August offering price
($310). Model and assumptions pushed in 5c20e717d ($310) before the market
pass; two outside reviewers then found an error and two unsupported margin
choices, fixed in 08dbccff9 ($281, section 2).

All values US dollars per diluted share (127.4M shares).

Fair value today      $281 per share, discounting at a 10.31% cost of equity; $323
                      weighting the bear, central and bull cases 25/50/25 (our weights)
Price                 $246.65, market data close 2026-10-26  →  upside 14% to central
                      (price 0.877 of fair value)
Five-year exit price  $467 at 2031-12-31: the mean of a long fade of returns ($444)
                      and an outside view from comparable companies' history ($490);
                      at 10 / 20 fade years $456 / $477; value-driver formula 9.9x
Five-year return      13.1% a year from $246.65 to $467; no distributions (all cash
                      is kept and sits in the exit price)
Bear / bull today     $111 / $620 from coherent operating cases
Confidence            30% (subjective, not calibrated): chance the 2031 value lands
                      within ±20% of $467
Moat                  Narrow. Celestica designs as well as builds hyperscalers' network
                      switches (its HPS line) and AI racks; its CCS margin rose from
                      6.2% (2023) to 8.9% (Q3 2026). Three customers are 66% of revenue
Market expects        The price is 8.3x our 2027 operating profit and 6.9x our 2031,
                      below the 8.7x our bear case pays in 2031 (market.txt): a 2027
                      peak followed by a decline
Price needs           One of, against our central: CCS growth 5.1 points a year lower
                      in 2028-31; CCS margin 0.9 point lower; 2027 revenue $5.2B lower
                      ($36.1B); or an exit at 0.71x the outside-view anchor (alpha
                      research odds)
Odds in our scenarios P(price justified): over 50% (subjective, not calibrated; odds.json)
Key driver            CCS growth 2028-2031: 5 points a year is −$34 / +$38 a share.
                      Next: CCS margin ±1 point ±$37; Celestica's own beta (1.56
                      against the peers' 1.19) −$34
Street                Average target $456.23, median $460, range $375-520 (market data via
                      research-check, 2026-10-26); 11 targets in the last quarter
                      average $445.09. Revenue 2027 $36.0B, 2030 $75.4B (13 and 7
                      analysts), set before the $40.0B outlook. An expectations
                      reference, not validation
```

**We rate Celestica a Buy at $281 a share against a $246.65 close, 12%
below our value.** Celestica beat its guide for the ninth quarter running
and gave a 2027 revenue outlook of $40.0B, 14% above the $35.0B we had
forecast; that alone adds about $47 a share. Two outside reviewers then
found that the first draft counted $700.8M of receivables sold to a bank
twice, and that it lifted the margin in every year when only 2027 is
sourced. We fixed both, and on their check of the margin through a cycle we
glide the 2031 margin of Celestica's main segment down to 7.7%. We still
expect AI hardware spending to slow after 2028. The stock has fallen 42%
since April while the market rose. Our estimate of its earnings rose over
the same months, so we read the fall as a lower multiple and sector
pressure, not a weaker business (section 6). The previous report rated it
a Hold at $286.

**Terms used below.**
- **CCS and ATS.** Celestica's two segments. CCS (Connectivity and Cloud
  Solutions) builds network switches, servers, storage and AI racks for
  hyperscalers and AI labs: 84% of Q3 revenue. ATS (Advanced Technology
  Solutions) builds for aerospace, industrial, health and chip-equipment
  customers. HPS (Hardware Platform Solutions) is the part of CCS where
  Celestica owns the design.
- **Bear, central and bull cases.** The central case is our best estimate
  and sets fair value; the bear is a severe but plausible bad outcome, the
  bull the matching good one. Each is one consistent business outcome.
- **Long fade and outside view.** Two estimates of what the company is
  worth at the end of 2031. The long fade extends the forecast 15 more years
  while growth slows to 3% and the return on new capital falls to its
  mature level. The outside view applies an EV/EBIT multiple (enterprise
  value over operating profit) from the past ten year-ends of Celestica and
  seven comparable manufacturers. The exit price is their average.
- **Mature return.** The return on new capital the long fade ends at.
- **Adjusted operating margin.** Celestica's non-GAAP measure: segment
  income over revenue, before stock pay, acquired-intangible amortization
  and restructuring.
- **Buy.** The price is at or below our central fair value.
- **Unblinded.** Written after the price was seen (above).

## 1. Q3 2026 beat our forecast and the guide

| | Our forecast (2026-10-15) | Range | Guide | Actual | In our range |
| --- | ---: | --- | --- | ---: | --- |
| Revenue ($M) | 5,567 | 5,400-5,750 | 5,250-5,550 | 5,829.7 | No, 4.7% above |
| Adjusted operating margin | 8.5% | 8.3-8.7% | 8.4% | 8.5% | Yes |
| Adjusted EPS | $3.09 | $2.90-3.20 | $2.88-3.08 | $3.30 | No, 6.8% above |
| 2027 revenue outlook ($B) | 35.0 | 33.8-38.0 | n/a | 40.0 | Above; graded on its due date, 2026-10-27 |

Graded in `../2026-10-15-cls/grades.json` from the release (8-K accepted
2026-10-26 20:23 UTC). Our revenue miss is the old report's choice to
assume half, not all, of the usual beat: Q3 beat the guide midpoint by 8.0%,
and the median of the last four quarters is now 6.9% (nine of nine
quarters above the midpoint, `output.txt`).

What the quarter showed (10-Q Q3 2026 and release; reported facts unless
marked):

- **Compute grew faster than networking.** Networking +68% to $3,263M;
  Compute & Storage +242% to $1,609M (AI compute volumes); HPS about
  $2.3B, +70%, but its share of revenue fell from 44% a year earlier to
  40%. CCS margin 8.9% (Q2 8.7%), from operating leverage.
- **Some working capital was financed by selling receivables.** Inventory
  rose $1.1B in the quarter and payables $1.5B. Celestica also sold $1.3B
  of receivables to a bank in Q3; $700.8M was outstanding at quarter-end
  (nil at June 30), and the program limit was raised from $450M to $1.0B
  in September. Counting the sold receivables, working capital was
  $1,450M, 6.8% of 2026 revenue, not the $750M on the balance sheet. We
  count them in working capital and deduct what is owed to the bank
  (section 3).
- **Cash.** $3,961M at quarter-end after the $3.39B August offering. The
  2026 free cash flow outlook was cut from $600M to $460M for "targeted
  working capital investments", and the 10-Q expects "a net use of cash in
  2027" (management claims).
- **Customers.** 35%, 17% and 14% of Q3 revenue, all CCS (Q2: 32%, 17%,
  14%); the top ten were 85%.
- **Guidance (management).** Q4 revenue $6.275-6.575B at 8.7% margin;
  2026 $21.0B; 2027 $40.0B revenue (+90%), 9.0% adjusted operating margin,
  $21.50 adjusted EPS, $1.5-2.0B capex; "2028 customer demand forecasts
  that are meaningfully higher than our 2027 revenue outlook."
- **Not yet available.** The call and Investor Day are on 2026-10-27 at
  8:00 ET; there is no transcript or slide deck yet, so this revision rests
  on the release and the 10-Q. The Investor Day may add multi-year targets
  (section 9).

## 2. What moved the value from $264 to $281

The last restatement of the 2026-10-15 report valued it at $263.97 under
today's method (the report was published at $286 under the method of its
day). This model rebuilds those inputs to the cent, then changes one group
at a time; each step is a full rerun (`output.txt`, "Bridge").

| Step | Kind | Central | Change |
| --- | --- | ---: | ---: |
| 2026-10-15 report, last restated | | $263.97 | |
| Same inputs rebuilt in this model | port check | $263.97 | 0.00 |
| Valued on 2026-10-26 | date | $264.75 | +0.78 |
| Comparable-company history refetched (one peer's newer year) | data | $264.75 | 0.00 |
| Q3 actual, Q4 guide, 2026-09-30 cash, debt, plant, 127.4M shares, sold receivables owed to the bank | data | $264.45 | −0.29 |
| 2027 revenue $41.4B from the $40.0B outlook (later growth rates unchanged) | data and judgment | $311.22 | +46.77 |
| 2027 margin at the outlook's 9.0% (CCS 9.25%); the old path after 2027 | data, then judgment | $311.65 | +0.43 |
| Tax 21% (the outlook's rate, was 20%) | data | $308.99 | −2.65 |
| Working capital 7% of revenue, sold receivables counted in it (was 5%) | data and judgment | $302.81 | −6.18 |
| CCS margin glides from 9.0% in 2028 to 7.72% in 2031 | judgment, after review | $286.71 | −16.10 |
| Bear and bull paths reset around the new 2027 | judgment | $286.71 | 0.00 |
| Mature return by rule H (was a judged 15%) | method | **$281.20** | −5.51 |

Of the 2027 step, $37.62 is management's outlook itself and $9.15 is our
assumption that Celestica beats it by half its usual margin ($40.0B exactly
gives $272.05).

**What the reviewers changed.** The model pushed before the market pass
gave $309.65. Two outside reviewers read it with the market in hand; each
change below rests on a filing, and each is a full rerun (`output.txt`,
"Changes after review"). All three were made after the price was seen and
all three moved the value toward it, so we name them here.

| Finding | Before | After | Central |
| --- | --- | --- | ---: |
| The $700.8M of sold receivables was added to working capital while the sale cash stayed in cash, with no claim. Collections go to the bank (10-Q), so the bridge now deducts it | no claim | −$700.8M at exit | −$3.31 |
| The CCS margin rose about 0.25 point in every year to 2031, but only 2027 is sourced (the 9.0% outlook). 2028-31 return to the old path | 9.25%, 8.95%, 8.65%, 8.45% | 9.0%, 8.7%, 8.4%, 8.2% | −$9.34 |
| Is 8.2% in 2031 a peak or normal? Our method ends a peak at normal unless dated evidence holds it. The CCS margin tracks HPS's share of revenue: 6.2% at 21% (2023), 7.4% at 29%, 8.2% at 41% (2025) (10-K FY2025). We read that line at a 35% share in 2031, our inference from compute growing faster (HPS fell from 44% to 40% of revenue in a year) | 8.7%, 8.4%, 8.2% (2029-31) | 8.57%, 8.15%, 7.72% | −$15.80 |

The mix line is fitted inside an upcycle, so it carries some operating
leverage; it is a floor on the argument that design content alone holds
the margin, not proof. The 2023 level, 6.2%, came before the AI build.
Gliding to it gives $230; the 2025 level, 8.2%, gives $297 (`output.txt`).

**Method changes since 2026-10-15.**
- **Rule H (2026-10-26).** Each case's mature return is now its own 2031
  return on the capital it holds, floored at the cost of capital and capped
  at Celestica's own median five-year history. Celestica's history is low:
  its windows ending 2019-2022 earned 0-6% on the capital it put in, when it
  was a slow-growing contract manufacturer, so the median is 6.2%. That is
  below the 10.14% cost of capital, so the floor sets every case's mature
  return at 10.14% (the old report judged 10% / 15% / 20%). The fade still
  starts at the forecast's own return on new capital, 74% in the central,
  and declines to 10.14%. Using only the two windows reported under US GAAP
  (2024-25, median 117%) would let each case keep its own held return and
  add $16. We keep the default because the slow-growth years resemble what
  our central becomes after 2030.
- **No plant-per-revenue floor (ruling 2026-10-26).** Our capex rule never
  had one: from 2028 capex is 1% of revenue plus $0.10 per dollar of the next
  year's growth, so plant per revenue dollar falls as revenue grows.
- **No own-history exit from a different growth era (ruling 2026-10-26).**
  The outside view's default, anchor (d), averages Celestica's own ten-year
  median EV/EBIT (10.0x) and its peers' (13.7x): 11.9x. Celestica's own leg
  was earned at a median 7.6% revenue growth over 2016-2025; our central
  grows 4.9% in 2031 and 5% in 2032. The leg comes from a comparable growth
  era, so it stays. If anything the two AI-era years (2024 18.8x, 2025
  32.1x) are the outliers in it; without them the leg is 9.0x and the anchor
  11.4x.
- **The judgment range is shown** (section 4) for both the exit multiple and
  the mature return.

## 3. The forecast keeps the post-2028 slowdown

`model.py` builds each segment's revenue from growth, applies a segment
margin, charges stock pay (0.4% of revenue) and restructuring (0.1%), runs
capex and depreciation on a plant schedule, sets working capital as a share
of revenue and keeps all cash to 2031. Our assumptions are labelled;
reported figures are from the Q3 2026 release and 10-Q.

| Central | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue ($B) | 21.2 | 41.4 | 49.8 | 54.6 | 56.3 | 59.0 |
| CCS growth | | +113% | +22% | +10% | +3% | +5% |
| CCS segment margin | | 9.25% | 9.0% | 8.57% | 8.15% | 7.72% |
| Adjusted operating margin | | 9.0% | 8.8% | 8.4% | 8.1% | 7.7% |
| NOPAT ($M) | 1,329 | 2,783 | 3,272 | 3,426 | 3,357 | 3,340 |
| Capex ($M) | | 2,000 | 975 | 714 | 839 | 885 |
| Owner free cash flow ($M) | | −292 | 2,193 | 2,911 | 2,965 | 2,864 |

- **2026-27 (data).** Q4 at the guide midpoint plus half the recent beat
  ($6,648M); 2027 at $41.4B, the outlook plus the same half-beat. CCS
  margin 9.25% in 2027, the level the 9.0% company outlook implies with ATS
  at 6.8%. 2027 capex $2.0B, the top of the guide, because our revenue is
  above the outlook.
- **2028-31 growth (judgment, unchanged).** CCS grows 22%, 10%, 3%, 5%; ATS
  5%, 5%, 4%, 4%. Management's 2028 claim supports the 22%. Nothing dated
  says when the AI build digests; in the past Celestica's revenue fell 11%
  in 2019 and stayed flat to 2021. We do not move the slowdown later on a
  management claim.
- **2028-31 margin (judgment, changed after review).** CCS 9.0% in 2028
  (the old path), then a glide to 7.72% in 2031 (section 2). ATS 6.8% in
  2027-28, then 7.0%.
- **Working capital (data and judgment).** 7% of revenue, counting the sold
  receivables (6.8% at 2026-09-30; 9.3% at the end of 2025), against the
  old 5%. Bear 9%, bull 6%. The $700.8M the bank paid for them is owed back
  through the collections it receives, so the bridge deducts it at exit,
  held at the 2026-09-30 balance. The bank can end the program on three
  months' notice.
- **Tax 21%; 127.4M shares held flat.** Stock pay is an expense, so it is
  not counted again as dilution.
- **Where we differ from management's 2027 EPS.** Our path gives $23.73 of
  adjusted EPS in 2027 against the $21.50 outlook. At our share count
  management's figure implies about $133M of net finance cost; our model
  earns $97M of net interest instead, on $3.7-3.9B of cash. Either
  management expects much less cash (more working capital), more shares,
  or its outlook is cautious, as its record suggests. Interest on that gap
  is worth about $1 a share; we disclose it and do not fit to it.

**Cases.** Bear: 2027 $34.0B (a program slip or shortage, 15% below the
outlook), CCS +3% in 2028 then −20% in 2029, margin down to 6.5%; 2031
revenue $30.4B. Bull: 2027 $46.0B, CCS +38%, +20%, +10%, +8%, margin 9.6%
then 9.5%; 2031 $87.7B.

## 4. The value is $281, within a $245-335 judgment range

| Case | 2031 revenue | 2031 NOPAT | Fade | Outside view | Exit | Fair value |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Bear | $30.4B | $1,409M | $192 | $178 | $185 | $111 |
| Central | $59.0B | $3,340M | $444 | $490 | $467 | **$281** |
| Bull | $87.7B | $6,148M | $876 | $1,186 | $1,031 | $620 |

Cost of equity 10.31% = 5.29% risk-free + 1.195 x 4.20% (Damodaran's
2026-10-01 pair; beta is the median of seven peers, Blume-adjusted). The
bridge adds year-end 2031 cash less operating cash, term loans, finance
leases and pension ($12,953M) and deducts the sold receivables ($700.8M):
$12,252M in the central, $96 a share at exit. The central exit is 11.2x
2031 EBIT. The fade and the outside view are 10% apart.

**Judgment range** (central operating case fixed, `output.txt`):

| Choice | Fair value |
| --- | ---: |
| Exit at the pooled 25th percentile of past exits against the anchor (8.2x) | $245 |
| Fade alone, no outside view | $267 |
| Own leg from 2016-2023 only, before the AI build (11.4x) | $276 |
| **Anchor (d), the default (11.9x)** | **$281** |
| Mature return from the 2024-25 US GAAP history (each case's own held return) | $297 |
| Peers' median alone, own leg dropped (13.7x) | $300 |
| Exit at the pooled 75th percentile (17.3x) | $335 |

**Sensitivities** (each alone, `output.txt`): 2027 revenue ±$1B ±$6.6;
CCS growth 2028-31 ±5 points a year −$34 / +$38; CCS 2029 growth at 20%
instead of 10% +$18; CCS margin ±1 point ±$37; CCS margin to 6.2% in 2031
$230, to 8.2% $297; working capital ±2 points of revenue ∓$6; 2027 capex
+$500M −$2; outside view ±20% ±$24; Celestica's own beta (1.56) −$34.

## 5. What the market expects and where we differ

At $246.65 the enterprise value is $29.1B (127.4M shares less $2.3B of net
cash after debt, pension and the sold receivables). That is 8.3x our 2027
operating profit and 6.9x our 2031 (`market.txt`). Our bear case exits at
8.7x 2031 profit. So the market prices our forecast as if Celestica were
already a shrinking contract manufacturer. Alternatively it doubts the
forecast: one of these alone reaches the price (`alpha research odds`):

- CCS growth 5.1 points a year below ours in 2028-31, about +17%, +5%, −2%,
  0%;
- the CCS margin 0.9 point lower, about 6.8% by 2031;
- 2027 revenue of $36.1B, 10% below the outlook a company that has beaten
  nine straight guides gave the same day;
- an exit at 0.71x the outside-view anchor, about 8.4x EV/EBIT, the bear's
  multiple on the central's profit.

The Street's targets (average $456) sit above our bull's exit path for
2026-27; its revenue is $36.0B for 2027 (before the outlook), $49.0B for
2028 (ours $49.8B) and $75.4B for 2030 (ours $56.3B). Our value differs from
the Street's on 2029-30, where we expect digestion, not on the next two
years. Our scenarios put more than half their weight above the price
(`odds.json`: P 58%, simulated median $281, at our central). The spread
is wide (10th to 90th $122-645), and most of it is the exit multiple
itself.

**Variant view.** The market and we agree that 2027 is a large year. We
part on what follows. The price pays as if profit peaks in 2027-28 and
then falls; we expect it to flatten at about $3.3-3.4B of NOPAT, because
Celestica now designs a large share of what it builds and the capacity
build is funded. What settles it: 2028 guidance (late January 2027 at the
earliest), and whether the CCS margin holds near 9% through 2027.

## 6. Why it keeps getting cheaper

The price fell 41.6% from 2026-04-27 to $246.65 while XLK, the technology
sector fund, rose 16.0% (`research-check`, `market.txt`). It fell 11.7% on
2026-10-22 alone, then 3.3% and 5.1% on the two days before the release.
The four questions research-check flags:

1. **Is our value stale or wrong?** Not stale: it is built on the release
   issued after today's close. It may still be wrong in the direction the
   price points. Two outside reviewers cut it from $310 to $281 on filing
   evidence (section 2). The margin through a cycle is the open question,
   and 6.2% by 2031 gives $230, below the price.
2. **Are forward owner earnings falling?** No. 2026 and 2027 outlooks rose
   (2026 revenue $16.0B in October 2025 to $21.0B; 2027 now $40.0B), and our
   2027-28 NOPAT is 17-21% above the old report's. Free cash flow is
   weaker: the 2026 outlook was cut to $460M and 2027 is a net use of cash
   (working capital), which our 7% charge carries.
3. **Is the market paying a lower multiple for this kind of business?**
   Yes, across AI hardware, not Celestica alone. Since 2026-04-27 Fabrinet
   fell 52.5%, Vertiv 38.0%, Jabil 19.1%, Credo 16.3% and Flex 14.5%
   (`market.txt`); Arista (+2.8%) and Nvidia (−0.3%) held. At 8.3x our 2027
   profit the market pays below our bear's 8.7x exit. We tested our exit
   against it: at 0.71x the anchor (8.4x) the value reaches the price
   (section 5). We keep the anchor because its legs are ten-year medians
   that include past downturns, but this is the de-rating path in
   section 7.
4. **Sector, factor or positioning pressure?** On 2026-10-22 the whole
   group fell together: Celestica −11.7%, Flex −11.1%, Fabrinet −10.8%,
   Credo −10.7%, Vertiv −7.8%, Arista −7.2%, XLK −3.3% (`market.txt`). That
   is a sector move, not news about Celestica. We found no Celestica
   announcement that day (news feed for NYSE:CLS, read 2026-10-26).
   The cause of the group's fall that day is not established; press
   accounts of October cite worries about debt-funded AI data-centre
   building and higher interest rates, and a nine-session fall in the
   semiconductor fund to 2026-10-16 (Benzinga and Reuters via search
   summaries, secondhand). We did not verify those for 2026-10-22, so we
   treat it as speculation.

Supported: 3 and 4 (a group de-rating). Open: 1 (the margin through a
cycle). Not supported: 2. What would change the call: a CCS margin below
8.5% in 2027 quarters (about −$29), or 2028 guidance that implies a fall
from 2027. A lower price alone does not change fair value. Chart read
(timing only, not an input): the close is at its 52-week low ($244.51 low
on market data), far below its 50- and 200-day averages ($329, $333), a falling
trend with no base yet.

## 7. Bear case and why the other side could be right

The bear ($111) is an AI spending pause: 2027 lands 15% below the outlook,
2029 CCS revenue falls 20%, and the margin returns to its 2023 level. Three
customers are two-thirds of revenue, and in Q3 inventory grew $1.1B in a
quarter, so a pause would hit revenue and cash together. The bear's exit is
8.7x 2031 EBIT.

**De-rating path.** If our central forecast holds but the market keeps
paying the bear's 8.7x at the end of 2031, the stock is worth $232 today
(`output.txt`), 6% below the price. Celestica fetched 8.4-14.7x at its
2016-2021 year-ends, when it grew 0-8% with concentrated customers. Two
pieces of evidence would keep the multiple there: hyperscaler capex guides
flattening for 2028, or a top-three customer moving a program to a
Taiwanese design manufacturer or in-house.

**The other side.** The case for Avoid is the margin and the multiple
together: if the CCS margin returns toward 2023's 6.2% and the market
keeps paying 8-9x, value is near $200. The bull's strongest evidence is
dated and specific: management says customers' 2028 forecasts are
"meaningfully higher" than $40.0B, and its record backs it, with nine
straight beats and four raises of the 2026 outlook. 20% CCS growth in 2029
instead of 10% alone adds $18. What decides it is whether the AI build is
a cycle (our view) or a long build-out at slowing growth. That will not be
dated before 2028 guidance.

## 8. Next results preview: Q4 2026, expected late January 2027 (date not announced)

| Forecast | Value | Range | Reason from the model |
| --- | ---: | --- | --- |
| Revenue ($B) | 6.648 | 6.45-6.90 | Guide midpoint plus half the last four quarters' median beat |
| Adjusted operating margin (%, company non-GAAP) | 8.8 | 8.6-9.0 | 8.7% guide; Q3 beat its 8.4% by 0.1 point |
| Adjusted EPS ($, company non-GAAP) | 3.65 | 3.45-3.80 | Our revenue and margin, $4.4M net finance, 20% tax, 127.4M shares |
| CCS segment margin (%) | 9.1 | 8.9-9.3 | Q3 8.9%, leverage on 16% more revenue |
| 2027 revenue outlook ($B, midpoint if a range) | 41.0 | 40.0-43.0 | The 2026 outlook was raised at every update |
| Q1 2027 revenue guide midpoint ($B) | 7.6 | 7.1-8.1 | Constant quarterly growth from the Q4 guide to $40.0B gives $7.614B |
| 2027 capex outlook ($B, midpoint) | 1.9 | 1.75-2.25 | Guide $1.5-2.0B; our revenue is above the outlook |

Each $1B of 2027 revenue above our $41.4B is worth about $6.6 a share
(through the model, later years growing from it). The old report's 2027
outlook forecast ($35.0B, range $33.8-38.0B) falls due on 2026-10-27 and is
graded then; the release puts it at $40.0B, above the range.

## 9. Catalysts and falsifiers

- **2026-10-27, call and Investor Day (company-announced).** Any 2028 or
  multi-year revenue target: one at or above $55B for 2028 (10% above our
  $49.8B) would move our 2028-29 path up; one below $45B moves toward the
  bear. Also 2027 capex, working capital, customer concentration and any
  multi-year margin target.
- **Late January 2027, Q4 2026 results** (expected; earlier Q4 releases
  were 2025-01-29 and 2026-01-28): section 8.
- **Falsifiers.** 2027 outlook cut below $38B: weight the bear. CCS margin
  at 8.5% or lower through 2027 (our 9.25%): about $29 lower if it lasts.
  Sold receivables above $1B, or customer deposits falling while inventory
  rises: working capital is worse than our 7%. A top-three customer below
  10% of revenue in a 2027 filing: toward the bear. A 2028 target at or
  above $55B with the margin held near 9%: our slowdown and margin glide
  are too low.

## 10. What the reviewers found and what we did

Two outside reviewers (Codex, read-only, and an Opus reviewer) read the
pushed model with the market and flags. Codex advised against landing;
the Opus reviewer advised landing with fixes.

| Finding | Answer |
| --- | --- |
| Sold receivables counted twice (both) | Fixed: claim deducted at exit, −$3.31 (section 2) |
| Margin lift after 2027 labelled data, sourced only for 2027 | Fixed: old path after 2027, labelled judgment, −$9.34 |
| 2031 CCS margin of 8.45% against 6.2% before the upcycle | Moved: glide to 7.72% on the HPS-mix line, −$15.80; 6.2% shown at $230 |
| Flag 25: down 41.6% since April against XLK +16%; −11.7% on Oct 22 | Answered in section 6 |
| Half-beat on the outlook, rule H floor, 11.9x exit, the ungraded 2027 outlook, the $310 offering-price exposure | Disclosed; unchanged |

## 11. Sources

- Celestica Q3 2026 press release, Exhibit 99.1 to the 8-K accepted
  2026-10-26 20:23:49 UTC,
  https://www.sec.gov/Archives/edgar/data/1030894/000103089426000049/cls-20260930prcondensedfs.htm
  (primary; `data/q3-2026-release.htm`).
- Celestica 10-Q for the quarter ended 2026-09-30, accepted 2026-10-26
  20:26:17 UTC,
  https://www.sec.gov/Archives/edgar/data/1030894/000103089426000050/cls-20260930.htm
  (primary; `data/10q-q3-2026.htm`), with its Exhibit 10.1 amending the
  receivables sale agreement.
- The 2026-10-15 report's sources: 10-K FY2025 (segment margins and HPS
  shares 2023-2025), 10-Qs Q1-Q2 2026, releases Q2 2024-Q2 2026, 8-Ks of
  2026-08-07 and 2026-09-11, Q2 2026 call notes.
- Market data annual statements (CLS and peers) and fiscal year-end enterprise
  values, fetched 2026-10-26 (`data/peer-income.json`,
  `data/exit-anchor.json`); peer weekly returns saved 2026-10-15.
- Market data daily closes for CLS, peers, XLK and SPY through 2026-10-26
  (`data/market-closes.json`); market data Street targets and estimates via
  `scripts/research-check.py`, 2026-10-26.
- News feed for NYSE:CLS, read 2026-10-26 (no Celestica story on
  2026-10-22); web search summaries of October 2026 AI-hardware and
  semiconductor declines (Benzinga, Reuters; secondhand, not verified).
- Damodaran implied equity risk premium and risk-free rate, 2026-10-01
  (the shared method's dated pair).

## Revision history

| Report | View | Pessimistic | Central | Optimistic | Central change | Price | Price read at (UTC) | Restated under | Blinding |
|---|---|---:|---:|---:|---:|---:|---|---|---|
| 2026-10-15-cls | hold | 100 | 286 | 530 | first | 315.27 | 2026-10-15T19:59:59Z | case-spread-2026-10-24 | partly unblinded |

- **2026-10-15, $286, Hold** (bear $100, bull $530). First report: 2027 at
  management's +65% floor ($35.0B), CCS slowing to 3-5% by 2030-31, exit
  the median of a judged 15x, a fade and an outside view. Partly unblinded
  (offering and award values seen before the model).
- **Restated 2026-10-16 to 2026-10-23, $318, then $260-264 (method).** The
  same forecast under the shared method's exit rules: the mean of fade and
  outside view (2026-10-16), anchor (d) (2026-10-18) and the case spread
  (2026-10-24). Last value $263.97, bear $99, bull $539.
- **2026-10-26, $281, Buy (+$17 from $264).** Data: Q3 2026 results and a
  $40.0B 2027 outlook (+$38 for the outlook, +$9 for our half-beat on it,
  −$3 tax, −$6 working capital, the sold receivables now a claim). Judgment:
  the 2028-31 growth path unchanged; the CCS margin back on the old path
  after 2027 and gliding to 7.72% by 2031 (−$16 net of the 2027 margin).
  Method: rule H's mature return, −$6. The blind draft was $310; the
  reviewers' three fixes took $29 (section 2). Made after the price was
  seen.